INTRODUCTION
The period following the delivery of a baby is a time of relief and joy for all involved. Although the 3rd stage of labor is usually uneventful, several significant complications especially postpartum hemorrhage (PPH) can be there. Postpartum hemorrhage is the major cause of maternal deaths in many low-income countries. 1 Every year about 14 million women worldwide suffer from PPH. 2 Most deaths (about 99%) from PPH occur in low-and middle-income countries compared with only 1% in industrialized nations. 3 However, recent studies have shown an increase in the incidence of PPH in developed countries as well. 4 The World Health
Organization (WHO) estimates that, of the 529,000 maternal deaths occurring every year, 136,000 or 25.7% take place in India, where two-thirds of maternal deaths occur after delivery, PPH being the most commonly reported complication and the leading cause of death (29.6%). In India, out of an estimated 25 million deliveries each year, 18 million take place in peripheral areas where maternal and perinatal services are either poor or nonexistent. India's stated goal is to reduce maternal mortality rate (MMR) from 212 in 2009 to 109 by 2015.
The WHO and professional bodies recommend active management of the 3rd stage of labor (AMTSL) for all vaginal births in order to prevent PPH. 5 The fewer the medical services available at the birth site, the greater the potential benefit of AMTSL in preventing PPH. 5 Administration of a prophylactic uterotonic agent immediately after the delivery of the baby is a vital component in the AMTSL. When PPH occurs, a number of medical and surgical interventions are used to control the bleeding. Oxytocin injection is the recommended first line uterotonic medicine for preventing and treating PPH because it is more effective than ergometrine and other uterotonics and has relatively fewer side effects. However, oxytocin is unstable at room temperature and requires special temperature storage conditions to remain effective, 6 which is a constraint in low-resource countries. In addition, the fact that oxytocin must be administered parenterally requires the involvement of skilled health personnel. The WHO has developed guidelines supporting the use of an uterotonic when the full package of AMTSL, which can be either oxytocin, 10 IU administered parenterally, or misoprostol, 600 µg JSAFOG administered orally. 7 The objective of this study is to compare the efficacy and side effects of misoprostol and oxytocin as uterotonic in AMTSL, particularly in poor resource settings.
MATERIALS AND METHODS
A prospective study was conducted in our labor room from January 2012 to 2013 to compare the use of IM oxytocin and rectal misoprostol in AMTSL. Two hundred pregnant women (parity < 5) were considered for this study who had uncomplicated singleton term pregnancy with known antenatal hemoglobin level and devoid of risk factors that might increase 3rd stage complications. Those 200 women fulfilling the inclusion criteria were randomized (computer based) into two groups: IM oxytocin 10 IU (n = 100) and rectal misoprostol 600 µg (n = 100).
Exclusion Criteria
• The presence of contraindication for the use of misoprostol, such as hypersensitivity or presence of medical conditions: Asthma, heart diseases, epilepsy, etc.
• The presence of risk factors for excessive 3rd stage blood loss: Grand multipara, uterine fibroid, multiple gestation, gestational hypertension with the HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome, polyhydramnios, previous PPH, cesarean delivery, coagulation abnormalities, precipitous labor (< 3 hours), chorioamnionitis, etc. Blood loss was estimated in mL by collecting the lost blood in a graded glass jar, soaked mops and for every patient the amount of total blood loss was calculated. Duration of the 3rd stage for every patient was noted. Hemoglobin (Hb%) concentration before and 12 hours after delivery was estimated for each patient. Side effects including nausea, vomiting, diarrhea, shivering, and elevated temperature > 38°C (within 1 hour of delivery) were recorded on a standardized proforma. Demographic data along with obstetric history, clinical examination were recorded. The amount of 3rd stage blood loss, additional oxytocic requirement, and side effects in each group were noted. The data obtained were analyzed using Statistical Package for the Social Sciences (SPSS) version 17.0 for frequency and cross tabulation. Chi-square test was applied to compare the nominal and ordinal variables with Yates correction wherever necessary. Paired sample t-test was used to compare the differences between the count variables at 5% level of significance.
RESULTS AND OBSERVATIONS
According to Table 1 , the age group distribution in IM oxytocin group and rectal misoprostol group does not differ significantly (p = 0.1470), with average mean age being 24.760 and 24.00 respectively. 95% Confidence interval (CI) between the two groups are 2.189 to 0.6694. Duration of 1st and 2nd stage of labor in both groups was statistically insignificant. According to Table 2 , in the duration of 3rd stage of labor, there was no significant difference. In IM oxytocin group, mean predelivery and postdelivery Hb was found to be 11.050 and 10.276 respectively. In rectal misoprostol group, mean predelivery and postdelivery Hb was found to be 11.084 and 10.308 respectively. On statistical analysis, the differences between each group were found insignificant (p-value = 1.242, relative risk = 1.00, 95% CI = 0.561 to 1.780). Mean Hb fall between IM oxytocin and rectal misoprostol was not found to be significant (p = 0.3507, 95% CI = -0.1109 to 0.0749). In IM oxytocin and rectal misoprostol group, 1 (2%) patient and 3 (6%) patients respectively, required additional oxytocics. On statistical analysis this difference again insignificant. According to Table 3 , side effects like nausea/vomiting, shivering and pyrexia (>38°C) were noted and compared between two groups. In IM oxytocin group, incidence of nausea/vomiting, shivering, and pyrexia were 2% each. In rectal misoprostol group, incidence of nausea/ vomiting, shivering, and pyrexia were 12, 26, and 10% respectively. On comparison and statistical analysis, the difference in nausea/vomiting between both the groups was not found to be significant (p = 0.117, RR = 3.688, 95% CI = 0.5945-22.882). Regarding difference of pyrexia between both the groups, it was not significant too (p = 0.20449, RR = 3.128; 95% CI = 0.5169 to 18.923). But, difference in shivering was found to be significantly high in rectal misoprostol group than in IM oxytocin group (p = 0.008, RR = 7.977; 95% CI = 1.195 to 53.228).
DISCUSSION
In the AMTSL, oxytocin is the ideal drug of choice and most effective dose is 10 units intramuscularly. 8 To substitute oxytocin and to prevent PPH, misoprostol was chosen because it has similar advantages and minimal side effects. Moreover, it is easy to use and does not require special storage conditions (i.e., can be stored easily at room temperature; is thermostable and light stable; does not require specific conditions for transfer) and has a shelf life of several years. These advantages make it a useful drug in reducing the incidence of PPH in developing countries. 9 In a study by Walley et al 10 regarding trial of misoprostol and oxytocin in the management of the 3rd stage of labor, the mean duration of third stage was 7.3 and 6.2 minutes for the oxytocin and misoprostol group respectively, difference between them were statistically insignificant. In another study by Ng et al 11 on the effect of oral misoprostol and IM oxytocin in the management of 3rd stage of labor, they found that the mean duration of 3rd stage between the two groups were not significant like our study. In our study, mean pre-and postdelivery Hb in IM oxytocin group were 11.050 ± 1.43 and 10.276 ± 1.43, the difference being not significant. In rectal misoprostol group, mean pre-and postdelivery Hb were 11.084 ± 1.32 and 10.308 ± 1.39, the difference being not significant again. The mean Hb% fall with IM oxytocin was 0.77 ± 0.258 and with rectal misoprostol was 0.75 ± 0.207, which were comparable and not significant statistically. Our study results regarding the pre-and postdelivery Hb% are comparable to other similar studies. In our study, mean pre-and postdelivery Hb% in IM oxytocin group were 11.050 ± 1.43 and 10.276 ± 1.43, with insignificant difference. In rectal misoprostol group, mean pre-and postdelivery Hb% were 11.084 ± 1.32 and 10.308 ± 1.39, with insignificant difference again. The mean Hb% fall with IM oxytocin was 0.77 ± 0.258 and with rectal misoprostol was 0.75 ± 0.207, 12 analyzed the side effects of misoprostol and oxytocin and revealed that fever with shivering was most frequent in misoprostol group (41%) as compared to oxytocin group (14%) with other side effects being insignificant. In another study by Parsons et al, 13 shivering and increase in temperature were significantly higher in misoprostol group than oxytocin with rest of the side effects being insignificant. Analysis by Ng et al 11 in a study comparing misoprostol and oxytocin shivering and pyrexia was significantly higher in the misoprostol group. In our study also, there were similar results. Moreover, the gastrointestinal side effects of nausea, vomiting, and diarrhea could be avoided by administering misoprostol rectally. Patients who developed pyrexia did not require any medication and temperature subsided within 6 to 8 hours. Parsons et al 13 in their comparative study of oxytocin and misoprostol found that the need for additional uterotonics was not significant in both the groups. In our study also, the need for additional oxytocics was 2 and 6% in the IM oxytocin and rectal misoprostol group respectively that was not significant. The conclusion of the WHO trial was that misoprostol should not replace oxytocin in centers where oxytocin is the established norm for prophylaxis of PPH. 14 The investigators in the WHO trial acknowledged that the use of misoprostol may be beneficial at the time of catastrophic bleeding or in situations where oxytocin is not readily available. They found that 600 µg of oral misoprostol was less effective than parenteral oxytocin in minimizing blood loss as defined by the incidence of discrete outcomes: Measured blood loss greater than 1,000 mL or use of additional uterotonics. We chose change in hemoglobin concentration as our primary outcome measure for two reasons. First, to find out the incidence of PPH, a very large study would be required to evaluate a significant change in PPH as the primary outcome. Such a study would need to be multicentered and may require undue time for completion. In the present study, only two woman in the oxytocin group had an estimated blood loss of >500 mL. Second, excessive blood loss may be difficult to define clinically, especially if it is based on subjective observations. Blood loss, based on clinical assessment, 13 is often underestimated. Therefore, change in laboratory criteria, such as hematocrit or hemoglobin concentration is a more objective measure. It is recognized that the objective laboratory measurement is serving only as a proxy for the clinical outcome of excessive blood loss. The American College of Obstetricians and Gynecologists suggests that the definition of PPH may be based on change in laboratory findings in the postpartum period. 13 This study has shown that rectal misoprostol appears to be as effective in minimizing blood loss in low risk women in the 3rd stage of labor as IM oxytocin, the current management recommended by the WHO. The major limitation of the study is that it was not double-blinded and also large multicentric trials would be needed to establish the fact that rectal misoprostol is as effective as IM oxytocin.
AT A gLANCE COMMENTARy 1. Scientific background on the subject: Postpartum hemorrhage is a major cause of maternal mortality, especially in developing countries. To prevent PPH, WHO and other professional bodies recommend AMTSL for all vaginal births. The uterotonics used can be either 10 IU IM oxytocin or 600 µg of misoprostol rectally. 2. What this study adds to the field: This study emphasizes the fact that misoprostol can be used to prevent PPH in a rural setting where it does not require expertise, and is also easily available and thermostable.
CONCLUSION
Ours is a developing country with poor resource settings in many centers. Oxytocin needs to be stored at a temperature of 2° to 8°C to maintain its efficacy. In such scenario, misoprostol is a better option with similar efficacy and safety profile like oxytocin. It is cheaper compared to oxytocin with easy administration and storage, even in rural settings. Therefore, the use of misoprostol in AMTSL can have significant contribution in reducing maternal mortality due to PPH.
